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Table 1
Enzyme Activities in Fibroblasts (in mU/mg protein) of Controls,
Patients with Phosphomannomutase Deficiency, and Three Patients
with Phosphomannose Isomerase Deficiency
PMI Activities PMM Activities
Controls 6.8 2.4 (7) 3.8  .9 (8)
PMM deficient 8.0  4.4 (13) .5  .3 (13)
Patient A .2, .3 6.3
Patient B .2, .8 3.2
Patient C .2, .2 3.5
NOTE.—Phosphomannomutase and protein were measured as de-
scribed elsewhere (Van Schaftingen and Jaeken 1995; Jaeken et al.
1997a). Phosphomannose isomerase was assayed at 30C in a reaction
mixture (1 ml) containing 50 mM Hepes, pH 7.1, 5 mM MgCl2, 25
mM KCl, 1 mM dithiothreitol, 0.6 mM NAD, 0.5 mM mannose 6-
phosphate, 2.5 U/ml glucose 6-phosphate dehydrogenase from Leu-
conostoc mesenteroides, and 10 mg/ml phosphoglucose isomerase with
10 ml of an extract containing 5–20 mg protein/ml. Control and PMM
deficient measures are mean values  SD. Where two data are given,
the values were obtained on two different subcultures.
Figure 1 Scheme of mannose metabolism. Phosphomannose
isomerase PMI; phosphomannomutase PMM; hexokinaseHK.
The horizontal bar indicates the defect in phosphomannose isomerase.
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Phosphomannose Isomerase Deficiency: A
Carbohydrate-Deficient Glycoprotein Syndrome with
Hepatic-Intestinal Presentation
To the Editor:
Carbohydrate-deficient glycoprotein (CDG) syndromes
are genetic diseases that are due to defects in the gly-
cosylation of glycoproteins (Jaeken et al. 1993, 1997b).
With one exception (Billette de Villemeur et al. 1995),
all reported patients presented moderate to severe brain
disease (Jaeken and Casaer 1997). The diagnosis is usu-
ally made by isoelectrofocusing of serum transferrin
showing different patterns of cathodal shift due to the
deficiency of the terminal sialic acid (Jaeken et al. 1984;
Stibler and Jaeken 1990). The majority of patients show
the so-called type I pattern characterized by an increase
of di- and asialotransferrin. About 70% of patients with
the type I pattern have a deficiency of phosphomanno-
mutase (PMM) (type IA) (Van Schaftingen and Jaeken
1995; Jaeken et al. 1997a), the enzyme catalyzing the
second step in the conversion of fructose 6-phosphate
to GDP-mannose (fig. 1), and mutations in the PMM2
gene have been found in all patients with a PMM de-
ficiency (Matthijs et al. 1997a, 1998).
Among the patients from which we analyzed the fi-
broblasts (Van Schaftingen and Jaeken 1995; Jaeken et
al. 1997a; Matthijs et al. 1997b), ∼30 did not show
PMM deficiency. On the rationale that type I glycosy-
lation pattern may be due to other enzymatic defects in
the pathway leading to GDP-mannose, the activity of
phosphomannose isomerase, which catalyzes its first
step, was systematically analyzed in the samples from
the latter patients. As shown in table 1, three of them
showed a marked deficiency in this enzyme, whereas
PMM activity was normal. Experiments in which ex-
tracts were mixed indicated that the deficiency was not
due to the presence of an inhibitor. As reported elsewhere
(Van Schaftingen and Jaeken 1995), PMI activity was
normal in PMM-deficient patients. For patient C, the
PMI deficiency was independently found at about the
same time by other investigators (Niehues et al.,
1998).This patient, who had a similar liver disease as-
sociated with protein-losing enteropathy (Freeze et al.
1997; Niehues et al., 1998) as patient A (see below) was
not further investigated in the present study. The parents
of patient B, but not of patient A, were available for
testing; surprisingly, normal activities of PMIwere found
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Figure 2 Sequence alignment showing the position of the mu-
tations in patient A. The sequences of the enzymes from Candida
albicans (canal), Saccharomyces cerevisiae (sacce), Emericella nidulans
(emeni), Caenorhabditis elegans (caeel), and man (human) are shown.
Numbering of the residues starts from the initiator methionine. Con-
served residues are in bold. Three of the four residues liganding Zn2
in the C. albicans enzyme are indicated by an asterisk (*). The mutated
residues are shown below the alignment.
in their leukocytes (mother 5.5 mU/mg protein; father
6.7 mU/mg protein; controls for ).5.4  0.9 n  6
On the basis of the available sequence of the PMI
cDNA (Proudfoot et al. 1994), primers were designed
for the amplification and analysis of PMI. Primers PMI-
Biot (5′-Biotin-CGA GCA TGG CCG CTC CGC-3′) and
PMI-R2 (5′-CCA GCT CTT CCA GGG TAT AC-3′)
were used to amplify the PMI cDNA from total RNA
isolated from fibroblasts according to established pro-
cedures (Sambrook et al. 1989; Matthijs et al. 1997b).
The amplified fragment was sequenced using three flu-
orescently labeled primers: PMI-F1: 5′-FITC-CCA ATC
AGG AAC TGA AAC TC-3′, PMI-F2: 5′-FITC-ACA
GGG TTG GCA CTT CAA TG-3′, and PMI-F3: 5′-
FITC-GAA TTT AGG GTG GCT GGC AG-3′. The
cDNA fragment generated using primer PMI-R2 and
PMI-F1 (identical to PMI-Biot but lacking the biotin)
was cloned in pCR.2 by use of the TA-cloning kit (In-
vitrogen). The mutations were retrieved by sequencing
with PMI-F1. To confirm the phase of the mutations,
two clones representing the two alleles of the patients
were entirely sequenced using the previously described
primers and the M13-reverse and universal primers.
Patient A was found to be compound heterozygous
for a CrT mutation at position 304, causing a SerrLeu
substitution at codon 102, and a TrC mutation at po-
sition 413, replacing Met at codon 138 by Thr (fig. 2).
Both mutations concern positions that are conserved
from Saccharomyces cerevisiae and Candida albicans to
human PMI (Proudfoot et al. 1994). The corresponding
amino acids are situated near the active site, as deter-
mined by X-ray crystallography of the C. albicans en-
zyme (Cleasby et al. 1996). The Glu residue adjacent to
Met138 (Glu138 in C. albicans corresponding to
Glu137 in human PMI) is one of the four residues in-
volved in binding the catalytic Zn2 ion. The Lys residue
at position 100 in C. albicans (corresponding to Lys99
in human PMI) points inward into the active site, and
the mutation at Ser102 may well affect this orientation.
Thus, the mutations in the PMI gene are likely to explain
the lack of activity of this enzyme in patient A.
Except for a polymorphism at codon 377 (GTA/GTG,
both coding for Val), no sequence variation was detected
in PCR-amplified cDNA from patient B. The presence
of the polymorphism allowed us to select and fully se-
quence two clones derived from different alleles. Since
there is no mutation, the low activity in fibroblasts of
patient B could be due to a decrease in the transcription
of the gene because of mutations either in the promoter
or in a transcription factor required for the expression
of the enzyme. The finding of a normal activity in leu-
kocytes of the parents argues for this second possibility,
if at least the same isozyme is expressed in fibroblasts
and leukocytes. The fact that the supposed genetic defect
in patient B is different from that in patient A probably
explains why the enzyme deficiency is not as pronounced
in the former.
The clinical description of patient A has been briefly
reported elsewhere (Billette de Villemeur et al. 1995).
He was the third child of unrelated Lebanese parents.
His siblings were healthy. He was admitted at the age
of 5.5 mo for chronic diarrhea since the age of 3 mo
and hypoglycemia with convulsions, coma, and apnea.
There was no dysmorphy. Liver was 6 cm below the
costal margin and firm. Stool culture showed Pseudo-
monas aeruginosa. Hypoglycemia tended to recur par-
ticularly after 4 h following feeding. Liver biopsy re-
vealed fibrosis of the portal spaces and microvesicular
steatosis. At the age of 10 mo, he was readmitted with
generalized edema secondary to hypoalbuminemia.
Weight was 6.7 kg ( ), length 65 cm (! P  7.8 ! P 3 3
), and head circumference 43 cm ( ). Gross69 ! P  44.23
motor development was moderately retarded. Liver was
unchanged. Liver function testing showed slightly in-
creased bilirubin (50 mM) and glutamate-oxaloacetate
transaminase (82 U/liter). IgG (2.6 g/liter) and IgA (0.32
g/liter) were decreased. Prothrombin time was 63%. Sev-
eral clotting and anticlotting factors were decreased: fac-
tor XI (20%), antithrombin III (45%), protein C (29%)
and total protein S (51%). There was intermittent slight
proteinuria and moderate hyperaminoaciduria (partic-
ularly of glycine). Further extensive metabolic screening
did not reveal the cause of the hypoglycemias. Serum
transferrin isoelectrofocusing, however, showed the typ-
ical CDG syndrome type I pattern (decreased hexa-,
penta- and tetrasialotransferrin, and increased di- and
asialotransferrin) but phosphomannomutase activity in
fibroblasts was normal. Radiological examination of the
intestine suggested malabsorption, with fragmentation
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and flocculation of the contrast substance. Sweat test
was normal as well as intestinal disaccharidase activities.
On endoscopy, fragility of the intestinal mucosa with
easy bleeding was noted. Histology of duodenal biopsies
showed partial villus atrophy with hypercellularity and
only rare and discrete lymphangiectasias. Repeat liver
biopsy at the age of one year showed a more pronounced
picture of congenital hepatic fibrosis with stellate fibrosis
of the portal spaces and proliferation of numerous bil-
iary canaliculi without any inflammation and without
notable alteration of the hepatocytes. Renal hyperech-
ogenicity was found on ultrasound examination. Treat-
ment consisted of Diazoxide, which normalized gly-
cemia, regular intravenous administration of
immunoglobulins and albumin, and nasogastric tube
feeding with only a hydrolyzed, MCT-supplemented
milk. He suffered from frequent bacterial as well as viral
gastroenteritis. At the age of 26 months, weight was 9
kg ( ) and length 77.5 cm ( ). He! P  10.8 ! P  823 3
had a large abdomen with pronounced collateral cir-
culation, numerous disseminated angiomas, and un-
changed hepatomegaly. Since oral feeding was still not
supported, the nasogastric tube feeding was changed to
tube feeding via a gastrostomy. Neurological examina-
tion was normal. He was last seen at the age of 2
years with persisting protein-losing enteropathy.9/12
However, psychomotor development was normal. He
died at the age of 4 years from an unknown cause.
Patient B had a similar clinical picture consisting
mainly of liver disease, which disappeared after the in-
troduction of solid food at 3 mo. The case will be more
extensively presented elsewhere.
PMM deficiency results in a multisystem disease with
severe neurological involvement and dysmorphy, be-
sides, usually mild, liver, intestinal, and other organ dis-
ease (Jaeken et al. 1993, 1997a, 1997b). PMI deficiency
causes the same kind of sialotransferrin electrofocusing
pattern as PMM deficiency, but its clinical presentation
appears to be quite different in that the disease was
enterohepatic in patients A and C and hepatic with mild
neurological signs in patient B. Different explanations
can be provided for the fact that the clinical manifes-
tations of PMI deficiency are mainly hepatic and intes-
tinal. A first one is the possible existence of different
isozymes of PMI, as is the case for PMM (Matthijs et
al. 1997a, 1997b; Pirard et al. 1997). The cDNA that
has been identified and sequenced by Proudfoot et al.
(1994) appears to be derived from a gene that is only
poorly expressed in liver, as shown by northern blot
analysis. Still, the fact that mutations in this gene lead
to liver involvement in patient A indicates that this form
of PMI is expressed in liver. Furthermore, all human
expressed sequence tags found in data banks seem to be
derived from this gene, except maybe one that could
possibly encode an isozyme. However, we have been
unable to PCR-amplify human liver and leukocyte
cDNA with primers designed on the basis of this
sequence.
A second explanation stems from the different posi-
tion of PMM and PMI in the pathway leading to the
formation of GDP-mannose. Both enzyme deficiencies
are expected to cause a decrease in the biosynthesis of
dolichol-pyrophosphate-oligosaccharide in the endo-
plasmic reticulum (Powell et al. 1994; Krasnewich et al.
1995), and both defects are indeed known to be lethal
in yeast (Kepes and Schekman 1988). There is, however,
a major difference between PMM and PMI in that the
latter, but not the former, can be by-passed by the low-
Km hexokinases. These enzymes can indeed convertman-
nose to mannose 6-phosphate, displaying for this sub-
strate a rather high affinity with mM in the case ofK 5m
the brain enzyme hexokinase I (Sols and Crane 1954).
In contrast, glucokinase—also known as “hexokinase
IV”—the major, if not the only, hexokinase present in
hepatocytes (Reyes and Cardenas 1984) has a very low
affinity for mannose with a Km equal to 33 mM ac-
cording to Weinhouse (1976) and is therefore rather in-
efficient to phosphorylate this substrate at the concen-
trations prevailing in plasma (50 mM in controls;
Etchison and Freeze 1997). Blood mannose, which de-
rives from glycoprotein degradation and alimentary
mannose in unknown proportion, is therefore most
likely sufficient to support N-glycosylation in tissues
other than the liver. The exception appears also to apply
to the intestinal mucosa, as evidenced by the marked
enteropathy found in patients A and C (Niehues et al.
1988; Freeze et al. 1997). Remarkably, the specific ac-
tivity of PMM is more than four times higher in the rat
mucosa than in other tissues, which indicates that its
GDP-mannose requirements are elevated (M. Pirard and
E. Van Schaftingen, unpublished data). Furthermore, it
is a tissue in which the glucose concentration is elevated,
due to active absorption from the intestinal lumen and,
during postabsorptive period, to equilibration with
blood glucose through Glut2 (Thorens et al 1988). Glu-
cose can therefore competitively inhibit the phosphor-
ylation of mannose. Difference in tissue involvement of
PMI deficiency could also possibly arise from difference
in expression of the specific, lowKmmannose transporter
(Panneerselvam and Freeze 1996), which appears to be
involved in the preferential utilization of radiolabeled
mannose over radiolabeled glucose in cultured fibro-
blasts (Panneerselvam et al. 1997).
A logical consequence of the fact that hexokinase
phosphorylates mannose to mannose 6-phosphate is that
PMI deficiency, unlike PMM deficiency (Jaeken and Ca-
saer 1997; Marquardt et al. 1997; Mayatepek et al.
1997), should be treatable by administration ofmannose
supplements. This appears to be the case for patient C
(Niehues et al. 1988; Freeze et al. 1997), in which we
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have also found PMI deficiency. Unfortunately, patient
A died before trials with mannose could be attempted.
It would be interesting to know if the improvement of
the symptomatology observed in patient B following in-
troduction of solid food is due to the presence of man-
nose in the latter.
Because of its very different clinical presentation, this
new type of CDG syndrome was probably not recog-
nized as a glycosylation defect until now. In 1985, the
same clinical picture as that of patient A and C was
reported as a new syndrome in four infants from the
northeastern part of Quebec. They died between the ages
of 4 and 21 mo. They had also antithrombin III defi-
ciency (Pelletier et al. 1985), a typical feature of CDG
syndromes. We strongly suspect that these patients had
a PMI deficiency. In conclusion, PMI deficiency is a
newly recognized, lethal but potentially treatable CDG
syndrome that should be searched for in unexplained
enteropathy and/or liver disease.
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Temperature-Sensitive Phenotypes of Peroxisome-
Assembly Processes Represent the Milder Forms
of Human Peroxisome-Biogenesis Disorders
To the Editor:
Peroxisome-biogenesis disorders (PBDs) are lethal he-
reditary diseases caused by abnormalities in the assembly
processes of peroxisomes (Moser et al. 1995). The per-
oxisome is a ubiquitous organelle involved in vital met-
abolic functions, such as oxidative processes involving
H2O2, b-oxidation of fatty acids, and biosynthesis of
plasmalogens (Van den Bosch et al. 1992 ). PBDs are
characterized by multiple defects in these functions, as
well as by the lack of morphologically normal peroxi-
somes. They are genetically classified into complemen-
tation groups (CGs), the number of which is x11 (Shi-
mozawa et al. 1993; Moser et al. 1995; Poulos et al.
1995). Each CG contains significantly different clinical
phenotypes—for example, Zellweger syndrome (ZS), ne-
onatal adrenoleukodystrophy (NALD), and infantile
Refsum disease (IRD). ZS patients have severe neuro-
logical abnormalities, dysmorphic features, hepatome-
galy, and multiple renal cysts, and most die at age !6
mo. NALD patients have similar symptoms, but they
survive considerably longer, dying during early child-
hood. In contrast, IRD patients do not exhibit significant
abnormalities in the CNS, and they have the longest
average life span among patients with PBDs (Lazarow
and Moser 1995; Moser et al. 1995). Although the
causal genes (PEXs) for several CGs have been cloned
and the mutations have been identified at the molecular
level (Shimozawa et al. 1992 ; Dodt et al. 1995; Wiemer
et al. 1995; Fukuda et al. 1996; Yahraus et al. 1996;
Chang et al. 1997; Okumoto and Fujiki 1997; Port-
steffen et al. 1997; Reuber et al. 1997), it is unknown
why such diverse clinical phenotypes occur in the same
CGs although, in all CGs, the phenotypes are very sim-
ilar. We report that milder forms of PBDs are charac-
terized by temperature-sensitive (TS) phenotypes of per-
oxisome-assembly processes in the fibroblasts of
patients.
In spite of the variations in the clinical features, the
fibroblasts from patients of all three PBD phenotypes
generally lack peroxisomes. Although the occurrence of
a reduced number of peroxisomes occasionally has been
noted in several PBD cell lines (Arias et al. 1985;Wiemer
et al. 1991; Slawecki et al. 1995), no correlation with
clinical features has been apparent. We assumed that
limited types of leaky mutations in the PEX genes could
be the causes of the milder forms of PBDs. As a possible
parameter representing such leakiness, we examined
temperature sensitivity. Fibroblasts from PBD patients
with different CGs were incubated at 30C and at 37C
and were subjected to immunofluorescence stainingwith
anti-catalase antibody. After 72 h incubation at 30C,
punctate staining of catalase typical of peroxisomes was
detected in the fibroblasts of all six patients with IRD
and in three of five of those with NALD, belonging to
four different CGs (fig. 1b and table 1), whereas no
peroxisomes appeared in the same cells after incubation
at 37C (fig. 1a). Catalase and the 70-kD peroxisomal
membrane protein (PMP70) were colocalized in these
